MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/ans.70575

Медицинская библиотека · ANZ journal of surgery · 2026

Oncological Outcomes After Margin-Negative (R0) Resection in Borderline Resectable Pancreatic Adenocarcinoma: Upfront Surgery Versus Neoadjuvant Treatment-A Contemporary Review.

Wiboonkhwan Nan-Ak

СтатьяОбзорСравнительное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Achieving a margin-negative (R0) resection in borderline resectable pancreatic cancer (BRPC) is a critical prognostic determinant. The optimal clinical strategy-neoadjuvant therapy (NAT) versus upfront surgery (UFS)-remains a key clinical question.

METHODS

This narrative review synthesized contemporary evidence from studies published between 2009 and 2025, encompassing a total of 5598 patients with BRPC. The analysis compared oncological outcomes between NAT and UFS, specifically focusing on resection rates, R0 resection frequency, and median overall survival (OS). Mixed-cohort studies lacking BRPC subgroup analysis were excluded.

RESULTS

Evidence from both comparative and single-arm studies indicated that the majority of cohorts achieved significantly higher R0 resection rates and improved median OS following NAT. Resection rates after NAT ranged from 29% to 90%, whereas UFS cohorts reported rates between 62% and 92%. Although resection was more frequent in UFS groups, NAT cohorts demonstrated superior oncological margins; R0 rates in NAT groups ranged from 23% to 100% compared to 14% to 90% in UFS groups. This translated into a survival benefit, with NAT groups achieving a median OS of 11.0 to 43.9 months versus 11.6 to 27.8 months for UFS. NAT also facilitated superior pathological downstaging and reduced lymph node positivity.

CONCLUSION

Neoadjuvant therapy, utilizing potent multi-agent regimens, significantly improves R0 resection rates and overall survival in BRPC and is increasingly recognized as the preferred clinical strategy. Currently, this survival benefit is not clearly established for patients with upfront resectable disease.

Для цитирования: Wiboonkhwan Nan-Ak. Oncological Outcomes After Margin-Negative (R0) Resection in Borderline Resectable Pancreatic Adenocarcinoma: Upfront Surgery Versus Neoadjuvant Treatment-A Contemporary Review.. ANZ journal of surgery. 2026. DOI: 10.1111/ans.70575.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.